Lucid Capital analyst Alex Fuhrman initiated coverage of Enhanced Group with a Buy rating and $15 price target. The firm says demand for longevity treatments has been rising and that Enhanced has a plan to bring \"exclusive concierge-level care into the mainstream.\" The company is well positioned to capitalize on longevity demand with its scalable direct-to-consumer platform, the analyst tells investors in a research note.
